Biomarkers: Critical Driver Shaping the Elevated Prevalence Of Heart Diseases As A Catalyst For Biomarkers Market Expansion Market in 2025

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

Biomarkers Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the biomarkers market has witnessed swift growth. The market size, which stands at $68.77 billion in 2024, is predicted to balloon to $78.14 billion in 2025, representing a Compound Annual Growth Rate (CAGR) of 13.6%. Factors such as advancements in genomics and proteomics technologies, the escalating incidence of chronic illnesses, an increased focus on personalized medicine, burgeoning demand for companion diagnostics, as well as the widening scope of drug development applications, are driving this growth during the historic period.

Biomarkers Market Size Forecast: What's the Projected Valuation by 2029?
The biomarkers market is predicted to experience a swift expansion in the upcoming years, reaching an estimated value of $135.14 billion in 2029, accruing at a compound annual growth rate (CAGR) of 14.7%. The growth during the forecast period can be credited to an intensified focus on disease prevention and early detection, the broadening application of biomarkers in oncology and immunotherapy, enhanced investment in precision medicine initiatives, the rise of liquid biopsy as a non-invasive method for biomarker detection, and an increasing favourability towards using biomarkers in drug discovery and development. Prominent trends during this forecast period encompass the evolution of multi-biomarker panels, the rise of exosome-based biomarkers, the adoption of point-of-care biomarker testing, integrating real-world data into biomarker research, and investigation of microbiome-based biomarkers.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

What Are the Drivers Transforming the Biomarkers Market?
The surge in cardiovascular ailments is anticipated to fuel the expansion of the biomarkers market in the projected timeline. There has been a pronounced rise in the use of biomarkers for heart disease patients in recent years. Presently, natriuretic peptides remain the most frequently used biomarker, aiding in identifying patients with heart failure. Biomarkers like circulating biomarkers with a high sensitivity C-reactive protein offer diagnostics for heart failure. Heart disease emerges as the leading cause of mortality for most racial and ethnic groups in the United States, thereby increasing the demand for biomarkers. For instance, a report by the American College of Cardiology from August 2022 predicted that all four cardiovascular risk factors would witness a surge in the United States between 2025 and 2060. Diabetes is expected to see the highest percentage increase of 39.3%, affecting 55 million people, followed by dyslipidemia (27.6% impacting 126 million), hypertension (25.1% affecting 162 million), and obesity (18.3% impacting 126 million). Furthermore, the projections indicate a significant rise in rates of cardiovascular diseases, most notably stroke (33.8% affecting 15 million) and heart failure (33.4% affecting 13 million), followed by ischemic heart disease (30.7% affecting 29 million) and heart attack (16.9% affecting 16 million). Consequently, with escalating heart diseases and associated fatalities, an upward trajectory is anticipated in the growth of the biomarkers market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

What Long-Term Trends Will Define the Future of the Biomarkers Market?
Key players in the biomarker market are concentrating their efforts on inventing groundbreaking solutions, such as a pioneering biological marker, to augment innovation through joint research, technology amalgamation, and solid clinical validation. This novel biological marker, a recent discovery, represents biological activities and assists in identifying or tracking health conditions. It could take the form of a molecule, a gene, or a cell property, carrying possible significance for tailor-made medicine. For example, Genialis, an American company specializing in computational precision medicine, introduced a first-rate biomarker in September 2024. This news-making biomarker improves the accuracy of predictions for patient reactions to KRAS inhibitors, enabling patient-specific treatment strategies and enhancing clinical results. Its wide usage in different types of cancer endorses effective drug creation and refines patient assortment for custom therapies.

Which Segments in the Biomarkers Market Offer the Most Profit Potential?
The biomarkers market covered in this report is segmented -

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers
2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases
3) By Type: Biomarker Of Exposure, Biomarker Of Diseases
4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies

Subsegments:
1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers
2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers
3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp

Which Firms Dominate the Biomarkers Market by Market Share and Revenue in 2025?
Major companies operating in the biomarkers market include Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Which Regions Offer the Highest Growth Potential in the Biomarkers Market?
North America was the largest region in the biomarkers market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6485

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.